CLINICAL TRIALS PROFILE FOR CARNITOR SF

All Clinical Trials for CARNITOR SF

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00227266 ↗	Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy	Completed	Abbott	Phase 2	2005-09-01	This is a multi-center trial to assess safety and efficacy of a combined regimen of oral valproic acid (VPA) and carnitine in patients with Spinal Muscular Atrophy (SMA) 2 to 17 years of age. Cohort 1 is a double-blind placebo-controlled randomized intention to treat protocol for SMA "sitters" 2 - 8 years of age. Cohort 2 is an open label protocol for SMA "standers and walkers" 3 - 17 years of age to explore responsiveness of efficacy outcomes. Outcome measures will include blood chemistries, functional testing, pulmonary function testing, electrophysiological evaluations, PedsQL quality of life assessment, quantitative assessments of survival motor neuron (SMN) mRNA from blood samples, growth and vital sign parameters. Six centers will enroll a total of 90 patients.
NCT00227266 ↗	Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy	Completed	Families of Spinal Muscular Atrophy	Phase 2	2005-09-01	This is a multi-center trial to assess safety and efficacy of a combined regimen of oral valproic acid (VPA) and carnitine in patients with Spinal Muscular Atrophy (SMA) 2 to 17 years of age. Cohort 1 is a double-blind placebo-controlled randomized intention to treat protocol for SMA "sitters" 2 - 8 years of age. Cohort 2 is an open label protocol for SMA "standers and walkers" 3 - 17 years of age to explore responsiveness of efficacy outcomes. Outcome measures will include blood chemistries, functional testing, pulmonary function testing, electrophysiological evaluations, PedsQL quality of life assessment, quantitative assessments of survival motor neuron (SMN) mRNA from blood samples, growth and vital sign parameters. Six centers will enroll a total of 90 patients.
NCT00227266 ↗	Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy	Completed	Leadiant Biosciences, Inc.	Phase 2	2005-09-01	This is a multi-center trial to assess safety and efficacy of a combined regimen of oral valproic acid (VPA) and carnitine in patients with Spinal Muscular Atrophy (SMA) 2 to 17 years of age. Cohort 1 is a double-blind placebo-controlled randomized intention to treat protocol for SMA "sitters" 2 - 8 years of age. Cohort 2 is an open label protocol for SMA "standers and walkers" 3 - 17 years of age to explore responsiveness of efficacy outcomes. Outcome measures will include blood chemistries, functional testing, pulmonary function testing, electrophysiological evaluations, PedsQL quality of life assessment, quantitative assessments of survival motor neuron (SMN) mRNA from blood samples, growth and vital sign parameters. Six centers will enroll a total of 90 patients.
NCT00227266 ↗	Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy	Completed	Sigma Tau Pharmaceuticals, Inc.	Phase 2	2005-09-01	This is a multi-center trial to assess safety and efficacy of a combined regimen of oral valproic acid (VPA) and carnitine in patients with Spinal Muscular Atrophy (SMA) 2 to 17 years of age. Cohort 1 is a double-blind placebo-controlled randomized intention to treat protocol for SMA "sitters" 2 - 8 years of age. Cohort 2 is an open label protocol for SMA "standers and walkers" 3 - 17 years of age to explore responsiveness of efficacy outcomes. Outcome measures will include blood chemistries, functional testing, pulmonary function testing, electrophysiological evaluations, PedsQL quality of life assessment, quantitative assessments of survival motor neuron (SMN) mRNA from blood samples, growth and vital sign parameters. Six centers will enroll a total of 90 patients.
NCT00227266 ↗	Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy	Completed	University of Utah	Phase 2	2005-09-01	This is a multi-center trial to assess safety and efficacy of a combined regimen of oral valproic acid (VPA) and carnitine in patients with Spinal Muscular Atrophy (SMA) 2 to 17 years of age. Cohort 1 is a double-blind placebo-controlled randomized intention to treat protocol for SMA "sitters" 2 - 8 years of age. Cohort 2 is an open label protocol for SMA "standers and walkers" 3 - 17 years of age to explore responsiveness of efficacy outcomes. Outcome measures will include blood chemistries, functional testing, pulmonary function testing, electrophysiological evaluations, PedsQL quality of life assessment, quantitative assessments of survival motor neuron (SMN) mRNA from blood samples, growth and vital sign parameters. Six centers will enroll a total of 90 patients.

Clinical Trial Conditions for CARNITOR SF

Condition Name

Condition Name for CARNITOR SF
Intervention	Trials
Spinal Muscular Atrophy	2
Carnitine Deficiency	2
B Acute Lymphoblastic Leukemia	1
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1	1

Condition MeSH

Condition MeSH for CARNITOR SF
Intervention	Trials
Muscular Atrophy	2
Atrophy	2
Precursor Cell Lymphoblastic Leukemia-Lymphoma	2
Leukemia, Lymphoid	2

Clinical Trial Locations for CARNITOR SF

Trials by Country

Trials by Country for CARNITOR SF
Location	Trials
United States	9
Canada	2
Netherlands	1

Trials by US State

Trials by US State for CARNITOR SF
Location	Trials
Ohio	2
Georgia	1
Texas	1
New York	1
Wisconsin	1

Clinical Trial Progress for CARNITOR SF

Clinical Trial Phase

Clinical Trial Phase for CARNITOR SF
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	1
Phase 3	1

Clinical Trial Status

Clinical Trial Status for CARNITOR SF
Clinical Trial Phase	Trials
Completed	2
Terminated	1
Not yet recruiting	1

Clinical Trial Sponsors for CARNITOR SF

Sponsor Name

Sponsor Name for CARNITOR SF
Sponsor	Trials
Abbott	2
Families of Spinal Muscular Atrophy	2
University of Utah	2

Sponsor Type

Sponsor Type for CARNITOR SF
Sponsor	Trials
Other	12
Industry	4
NIH	1

CARNITOR SF Market Analysis and Financial Projection

Last updated: April 28, 2026

Clinical trials update, market analysis, and projection for Carnitor SF

What is Carnitor SF and what does it treat?

Carnitor SF is an L-carnitine oral solution (a carnitine supplement). L-carnitine is used to support fatty-acid transport and to treat carnitine deficiency states, with prescribing typically focused on:

• Primary (genetic) carnitine deficiency
• Secondary carnitine deficiency associated with medical conditions and/or drug exposures

The product naming “SF” is a formulation/brand variant used by local markets; the active moiety is L-carnitine (Carnitor brand lineage).

Which clinical trials are most relevant right now?

No complete, reliably citable, up-to-date global clinical-trial package (trial registry links, current recruitment status, and result publications) can be produced from the information provided. As a result, a complete “clinical trials update” covering:

• trial phase,
• start and completion dates,
• recruitment status,
• endpoints and results,
• and the most recent regulatory submissions tied to trial milestones,

cannot be compiled accurately.

What does the market look like for L-carnitine therapy?

Carnitor SF sits within the broader market for L-carnitine and carnitine supplementation used for inherited metabolic disorders and drug-induced or disease-associated secondary deficiency. The market’s demand drivers are structurally tied to:

• diagnosed carnitine deficiency prevalence (primary forms are rare but with sustained treatment need)
• hospital and specialty dispensing for metabolic disorders
• life-long or long-duration therapy in many diagnosed patients
• payer and guideline behavior that tends to favor established, branded supplements in some regions

However, generating a precise market size forecast for Carnitor SF specifically requires product-level inputs (country coverage, formulation-specific price points, channel mix, and reimbursement status) that are not present in the information provided.

Market projection: what can be projected with proof?

A projection for Carnitor SF needs at least:

• sales baseline (units or revenue),
• geography and channel segmentation,
• pricing/reimbursement trajectory,
• competitive set (other L-carnitine formulations and brands),
• patent/registration landscape and likely generics/biosimilars risk.

Those inputs are not available in the provided data, so a defensible projection cannot be produced.

---

Key competitive landscape (what matters for L-carnitine brands)

Even without Carnitor SF-specific numbers, the competitive dynamics that control near- to mid-term uptake for L-carnitine products typically hinge on:

• Formulation substitutability
  L-carnitine is usually considered substitutable across oral solutions/tablets in many payer decisions, so pricing and tender outcomes can dominate.

• Availability and supply reliability
  Specialty metabolic therapies often face fill-rate constraints; supply disruptions create short-term share losses but can also support rebound once availability returns.

• Reimbursement and formulary inclusion
  In many systems, patients access via specialty pathways, where formularies and prior authorization criteria shape penetration.

• Generic entry risk
  L-carnitine as an active ingredient is widely available as generics in many jurisdictions; brand differentiation tends to be formulation, labeling, packaging, and distribution reach.

---

Business outlook: what to watch next

For Carnitor SF, the near-term investment and commercial outlook usually turns on three measurable items:

1. Regulatory and labeling continuity in the target markets where “SF” formulation is positioned.
2. Tender and reimbursement outcomes in hospital procurement for metabolic disorder products.
3. Supply chain performance (availability, lead times, and batch consistency).

A clinical-trial-driven repricing or indication expansion is less common for commodity actives like L-carnitine unless a specific new formulation, dosing strategy, or population earns new evidence.

---

Key Takeaways

• Carnitor SF is an L-carnitine oral solution used for carnitine deficiency states (primary and secondary).
• A complete, proof-cited clinical trials update for Carnitor SF cannot be generated from the provided information.
• A Carnitor SF-specific market size and forecast cannot be produced without product-level baseline sales, geography, and competitive/pricing details.
• The practical market drivers for L-carnitine brands are reimbursement, formulary access, procurement/tender outcomes, and supply reliability.

---

FAQs

1. Is Carnitor SF the same as generic L-carnitine?
   It is the L-carnitine active in a specific brand/formulation variant; substitutability depends on region, labeling, and payer formulary rules.

2. What patient population uses Carnitor SF?
   Patients with primary inherited carnitine deficiency and secondary carnitine deficiency linked to medical conditions or drug exposures.

3. Will new clinical trials likely expand Carnitor SF indications soon?
   For established actives like L-carnitine, major indication expansion is less common unless a specific formulation or dosing strategy generates new regulatory-grade evidence.

4. What drives revenue for L-carnitine brands?
   Reimbursement and procurement (tenders/formulary inclusion), pricing, and consistent supply are typically the largest commercial levers.

5. How does generic competition affect L-carnitine brands?
   It usually pressures price unless the brand holds advantages in formulation, labeling, or procurement contracts that preserve share.

---

References

[1] No sources were provided in the prompt to cite.